PPARG and breast cancer: In another study, treatment with 6-OH-11-O-hydroxyphenanthrene, an RXR agonist, potentiated the ability of pioglitazone, a PPARγ ligand, to impede mammosphere formation in MCF-7 breast cancer cells [32].